Urinary Tissue Inhibitor of Metalloproteinase-2 (TIMP-2) • Insulin-Like Growth Factor-Binding Protein 7 (IGFBP7) Predicts Adverse Outcome in Pediatric Acute Kidney Injury
2015
Background
The G1 cell cycle inhibitors tissue inhibitor of metalloproteinase-2 (TIMP-2) and insulin-like growth factor-binding protein 7 (IGFBP7) have been identified as promising biomarkers for the prediction of adverse outcomes including renal replacement therapy (RRT) and mortality in critically ill adult patients who develop acute kidney injury (AKI). However, the prognostic value of urinary TIMP-2 and IGFBP7 in neonatal and pediatric AKI for adverse outcome has not been investigated yet.
Keywords:
- Renal replacement therapy
- Insulin-like growth factor-binding protein
- Gastroenterology
- Acute kidney injury
- Sepsis
- IGFBP7
- Tissue inhibitor of metalloproteinase
- Biomarker (medicine)
- Urinary system
- Pathology
- Internal medicine
- Medicine
- Interstitial nephritis
- Area under the curve
- Prospective cohort study
- Surgery
- Septic shock
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
36
References
57
Citations
NaN
KQI